With the fast progress and deeper understanding of CAR-T cell therapy, finding a better solution other than lentivirus transduction is more requested, to overcome the functional limitation on random insertion, uncontrolled copy number of CAR insertion and to overcome the capacity limitation of GMP lentivirus manufacture.
In this webinar, we will introduce non-viral solutions for cell therapy development: Starting from how to set up the non-viral work flow, the webinar will present how to use CRISPR-HDR protocol for precise target knock-out and gene knock-in in one step. Additionally, we will explore strategies to further improve the editing efficiency that has been proved on the primary T cell, NK cell, and iPSC. We will also provide solutions for large fragment knock-in via transposon systems. Finally, we will present a few early clinical data about CAR-T therapies which are manufactured by non-viral gene editing methods to illustrate its feasibility for clinical application.
Dr. Lumeng Ye
Director of Novel Therapeutic Material Development, R&D Department, GenScript Biotech
Dr. Lumeng Ye, joined GenScript at the end of 2017, as a senior scientist in molecular biology. Before joining GenScript, she got her Ph.D. from Vrije Universiteit Brussel in Bio-engineering and postdoc training in synthetic biology at Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark. After joining GenScript, her work has focused on developing non-viral DNA payloads for gene editing and processes for gene and cell therapy.
